Aim: The influence of sample handling on soluble urokinase plasminogen activator receptor (suPAR) concentrations in serum and EDTA plasma was studied in 16 healthy premenopausal women. Method: Blood was collected in dry tubes and tubes containing EDTA and kept at 4°C or 20°C for 1, 3, 8, 24 or 72 hours before processing into serum or EDTA plasma. In addition, serum and EDTA plasma were frozen and thawed 1-8 times. All suPAR measurements were performed by ELISA. Results: No significant differences were found between serum or EDTA plasma suPAR concentrations when whole blood samples were kept for 1, 3, 8 or 24 hours. Significantly higher suPAR levels were found in samples kept for 72 hours at 20°C compared to samples processed into serum or EDTA plasma after short-term storage for no more than 24 hours after collection. No significant differences were observed when whole blood was kept at 4°C for up to 72 hours. Repeated freezing and thawing had no significant effect on the serum and EDTA plasma suPAR levels. Conclusion: suPAR values in blood samples are dependent on the handling procedures of the samples. All samples of whole blood must be processed into EDTA plasma or serum within 24 hours if kept at 20°C and within 72 hours if kept at 4°C. However, repeated freezing/thawing cycles had no influence on suPAR values in the samples. (Int J Biol Markers, 2001; 16: 233-9)
INTRODUCTION
The urokinase plasminogen activator receptor (uPAR) is a 55 kDa highly glycosylated protein consisting of three homologous extracellular domains attached to the cell membrane via a glycolipid anchor (1, 2) . The receptor binds pro-uPA and facilitates the activation of pro-uPA to active uPA and thereby also the conversion of plasminogen to the active enzyme plasmin, which is involved in extracellular matrix degradation (3) . The major binding site for pro-uPA is within the amino-terminal domain of uPAR, but high-affinity binding of pro-uPA requires domain interactions (4) . uPAR can be cleaved in the linker region between domains 1 and 2 by physiological concentrations of several proteases, including uPA and plasmin, resulting in a truncated receptor unable to bind pro-uPA (5) (6) (7) . Also, the domain 1 liberated by such cleavage appears to have little or no ligand binding capacity (4) . In addition, uPAR can be liberated in vitro from the cell membrane by the action of phospholipase D (8) but the enzymes responsible for uPAR cleavage under physiological conditions remain unknown. The soluble three-domain receptor (suPAR) has been detected in several types of bodily fluids including blood, urine and cyst fluid from ovarian cancer (9) (10) (11) (12) , and it was recently reported that suPAR in blood can originate from monocytes/macrophages, neutrophils and endothelial cells (13) (14) (15) .
In 1997 Stephens et al reported that soluble forms of uPAR can be measured in blood from healthy blood donors in plasma prepared with EDTA, heparin or citrate as anticoagulant as well as in serum. In addition, no correlation was found between suPAR concentration and donor age, whereas suPAR concentrations in serum from female donors were significantly higher than serum su-PAR levels found in male donors (9) . Measurements of suPAR in blood samples from patients with breast cancer (9), patients with prostate cancer (16) and patients with ovarian cancer (17, 18) showed significantly elevated su-PAR levels compared to the levels found in healthy sexmatched controls. When correlating preoperative suPAR levels with patient outcome a Dukes-independent, highly significant association between elevated suPAR levels and poor prognosis was found in a cohort of 591 colorectal cancer patients (19) and confirmed in a study including 173 patients with rectal cancer (20) . In addition, elevated suPAR levels in blood have been shown to be independently associated with poor survival in ovarian cancer patient survival (17, 18) .
In plasma from patients with rheumatoid arthritis, the suPAR concentration was shown to be related to disease activity (21) . suPAR levels have also been determined in serum of patients suffering from HIV-1 infection and an increasing serum suPAR level was significantly associated with AIDS-related death (22) .
These findings suggest that measurements of suPAR in blood can be of value in the management of patients suffering from different diseases including cancer and we therefore considered it relevant to examine the effect of different conditions of whole blood storage until processing into EDTA plasma and serum on the stability of the suPAR concentration measured.
MATERIAL AND METHODS

Subjects
The study was based on three different sets of blood samples collected from 26 volunteers, healthy premenopausal Danish women (Set A: samples from eight women; Set B: samples from eight women; Set C: samples from ten women). Whole blood was collected in tubes containing EDTA for preparation of EDTA plasma or in dry tubes for serum preparation. All samples of whole blood were processed into serum or ETDA plasma by centrifugation at 2000xg for 10 min, and the supernatants were stored at -80°C until suPAR analysis.
The samples of sets A and B were used to investigate the effect on suPAR levels of different storage times and temperatures of whole blood samples before they were processed into EDTA plasma and serum. The samples of set A consisted of whole blood from eight women collected simultaneously in tubes containing EDTA and in dry tubes. The blood in tubes containing EDTA was kept at 4°C or 20°C for 1, 3, 8, 24 or 72 hours, while that in the dry tubes was kept for 1, 8 or 24 hours. Subsequently, the samples were centrifuged and processed into either EDTA plasma or serum. The samples of set B consisted of whole blood from eight women collected in dry tubes and kept at 4°C or 20°C for 1, 3 or 72 hours before centrifugation.
In addition, in order to investigate the effect of repeated thawing and freezing we prepared a set C consisting of whole blood from ten women collected in tubes containing EDTA and in dry tubes. The samples were processed into EDTA plasma and serum within one hour of blood collection. Each EDTA plasma and serum sam-ple was then divided into eight smaller tubes and immediately frozen. After 24 hours seven tubes were thawed at room temperature, kept at 4°C for one hour and then refrozen. This process was repeated daily, leaving one additional tube frozen each day, until the last tube was thawed and refrozen a total of eight times.
Assay
Serum and EDTA plasma suPAR levels were measured with the kinetic enzyme-linked immunosorbent assay (ELISA) described by Riisbro et al (23) , which is a modified version of the previously described suPAR ELISA (19) . The modifications were made because of the finding of a variable and often high, non-specific signal in non-coated blocked wells when analyzing serum, while a constant low non-specific signal was obtained with citrate and EDTA plasma. The non-specific signal could be totally removed in assays of plasma samples and significantly lowered in assays of serum samples by addition of 50 U/mL of unfractionated heparin (Sigma Chemical Company, St. Louis, MO) to the assay buffer [0.81 M Na 2 HPO 4 (Merck, Darmstadt, Germany), 0.19 M NaH 2 PO 4 (Merck), 0.1 M NaCl (Merck), 10 g/L bovine serum albumin (Fraction V, Boehringer-Mannheim, Penzberg, Germany), 1 g/L Tween-20 (Merck), pH 7.2]. In addition, coating was performed with 3 µg/mL of the mouse monoclonal anti-uPAR antibody R2 overnight at 4°C. Samples and standards (recombinant human suPAR, 1.0-0.0 ng/mL) were incubated for two hours at 30°C, and detection was performed with 1 µg/mL of rabbit polyclonal anti-suPAR antibody (immunoabsorbed against mouse IgG) overnight at 4°C. The remaining part of the assay was performed as previously described (19) . All incubations were performed using a volume of 100 mL/well. This suPAR assay was rigorously tested with dilution and recovery experiments, and immunoabsorption as described previously (23) . The intra-assay variation of an EDTA plasma pool (2.3 ng/mL) was 9.6%. The interassay variations of two controls analyzed on the plates used in this study were 5.0% high control (3.8 ng/mL) and 5.6% low control (2.1 ng/mL). All measurements were performed in duplicate.
Statistical analysis
All statistical analyses were performed using Statview software version 5.0 (SAS, Institute, Cary, N.C.). Repeated measurements were analyzed using the multivariate analysis of variance criterion to test the hypothesis of no time effect (24) . This analysis was also applied to the samples in set C including the ratio between serum and EDTA plasma. suPAR concentrations in serum and EDTA plasma were compared by analysis of variance (ANO-VA), adjusting for temperature and time. The significance level was set at 5%.
RESULTS
Set A
In the samples of whole blood kept at 4°C or 20°C for 1, 8 or 24 hours before processing into serum no significant difference was found in suPAR concentrations (p=0.34 and p=0.27 for 4°C and 20°C, respectively). Figure 1 shows the serum suPAR concentration in samples kept at different temperatures and for different times for each of the eight women. Similarly, no difference was found in EDTA plasma suPAR concentration when the samples of whole blood in tubes containing EDTA were kept at 4°C for 1, 3, 8, 24 or 72 hours before centrifugation (p=0.32) (Fig. 2) . In contrast, a significant increase in suPAR concentration was found when the plasma samples were kept at 20°C before processing (p=0.009) (Fig. 2 ). In addition, Figure 2 shows that the suPAR concentration in the samples left for 72 hours before processing into EDTA plasma in six of the eight individuals gave rise to the high- (1, 8 and 24 hours) . No association was found between suPAR concentration and time to processing at either 4°C (p=0.34) or 20°C (p=0.27). (1, 3, 8, 24 and 72 hours). No statistically significant difference was found when the samples were kept at 4°C (p=0.34), while a significant difference in suPAR levels was found when the blood samples were kept for 1, 3, 8, 24 or 72 hours at 20°C before processing into EDTA plasma (p=0.009). The highest suPAR concentration was measured after 72 hours' storage in six of the eight women. No difference was found in samples stored for 1-24 hours before processing (p=0.53). est suPAR concentration. Exclusion of the samples kept for 72 hours from the analysis resulted in no difference in the suPAR concentration in EDTA plasma prepared after storage of the whole blood in tubes containing EDTA at 20°C for 1, 3, 8 or 24 hours (p=0.53).
Fig. 2 -suPAR concentrations in EDTA plasma derived from whole blood collected in tubes containing EDTA and kept for 1, 3, 8, 24 or 72 hours at 4°C (A) or 20°C (B) before processing into EDTA plasma. The suPAR concentrations for each individual are shown ranked by time
In this set of samples (set A) it was possible to compare the serum and EDTA plasma suPAR concentration in the individuals. The serum suPAR levels were significantly higher than the EDTA plasma suPAR levels (ANOVA, p <0.0001). The ratio between the serum and EDTA plasma suPAR concentration was constant, independent of the time before the whole blood samples were processed (mean ratio ± standard deviation (SD), at 4°C: 1.17±0.14 after 1 hour, 1.19±0.25 after 8 hours and 1.21±0.17 after 24 hours; p=0.63; at 20°C: 1.19±0.11 after 1 hour, 1.20±0.18 after 8 hours and 1.14±0.12 after 24 hours; p=0.60). No differences were found when the ratios observed in samples kept at different temperatures were compared (ANOVA p=0.29).
Set B
No differences were found in serum suPAR concentrations when whole blood was kept at 4°C for up to 72 hours before centrifugation (p=0.57). These results are shown in Figure 3 . In contrast, in whole blood kept at 20°C for 1, 3 or 72 hours before processing into serum a significant difference was found in the serum suPAR concentration (p=0.005). As shown in Figure 3 the observed difference is due to a consistently higher suPAR level found in the samples left for 72 hours, whereas no significant differences in suPAR concentrations were observed in serum samples left for one or three hours (p=0.11). To investigate if the increase in suPAR concentration in whole blood left at 20°C for 72 hours before centrifugation occurred due to non-specific crossreactivity between the different components in the suPAR ELISA, two modified formats of the assay were prepared: 1) by deleting the coating antibody from the coating buffer and 2) by deleting the primary detection antibody (rabbit polyclonal antihuman suPAR antibody). All other parts of these modified assays were performed according to the assay protocol. The samples stored for three or 72 hours at 20°C before centrifugation were analyzed once again in the regular assay and in the two modified formats of the assay and yielded a signal at the assay background level for all analyzed samples (data not shown).
Set C
The suPAR concentration in these samples did not change during the freeze-thaw cycles (p=0.28 and p=0.58 for serum and EDTA plasma, respectively). Figure  4 shows the suPAR concentrations in serum and EDTA plasma from the ten women after each freeze-thaw cycle. The ratio between suPAR levels among these 80 paired serum and EDTA plasma samples was determined; the mean ratio (serum suPAR/EDTA plasma suPAR) was 1.23, SD 0.12, coefficient of variation 9.9%.
DISCUSSION
Earlier studies of other biochemical markers have shown that serum and/or plasma concentrations of these markers may be dependent on preparation conditions (25, 26) and we therefore found it relevant to investigate (1, 3 and 72 hours) . No difference was found in suPAR concentrations in samples kept at 4°C (p=0.57), while a significant difference was found when comparing suPAR levels in whole blood kept for 1, 3 or 72 hours at 20°C (p=0.005). suPAR concentrations in samples stored for 1 or 3 hours at 20°C showed no difference (p=0.11).
the influence of sample handling on serum and EDTA plasma suPAR levels. This study shows that suPAR levels were sensitive to the conditions in which whole blood was kept before being processed into either serum or ED-TA plasma. In whole blood collected into tubes containing EDTA, suPAR was stable at 4°C for 1, 3, 8, 24 and 72 hours, whereas a significant difference was found in the suPAR concentrations when the samples were kept at 20°C, i.e., a minor but significant increase in suPAR levels was observed in samples kept for 72 hours. Similarly, no differences were found in serum suPAR samples kept at 4°C for up to 72 hours, while the serum suPAR concentrations were significantly increased in whole blood samples kept for 72 hours at 20°C before processing into serum as compared to samples kept for up to 24 hours at 20°C. These studies indicate that the release of suPAR from blood cells is time and temperature dependent. Similar results were obtained by Mustjoki et al (15) , who used another format of the suPAR ELISA.
Many studies on new serological markers are performed with archival blood material which was often used previously for several other analyses. A very important finding in our study is therefore that suPAR in both EDTA plasma and serum is stable with repeated freezing and thawing up to at least seven times, but it still remains unclear whether long-term storage has any influence on the suPAR levels.
The ELISA used for measurement of suPAR was rigorously tested with recovery and dilution experiments performed with serum and EDTA plasma. In addition, immunoabsorption of serum and EDTA plasma on cyanogen bromide-activated Sepharose™4B coupled with uPAR-specific antibodies showed that the signal obtained in the ELISA could almost totally be removed, which indicates that the assay is specific for measurements of suPAR (23) . The specificity of the assay was also tested in the present study by analysis of the serum samples with high suPAR concentrations in two modified ELISA formats. These analyses only gave rise to a signal at the background level indicating that the increase in suPAR concentration observed over time at 20°C was real and not related to unspecific crossreactivity.
One of the most likely explanations for the time-dependent increase in suPAR levels in both serum and ED-TA plasma when kept at 20°C is that proteases and lipases present in the whole blood preparation cleave uPAR bound to the cell surfaces of neutrophils and monocytes (14) . The increase in suPAR concentration could also be explained by lysis of cells and thereby release of intracellular uPAR and/or enzymes (proteases and lipases), thus increasing the suPAR concentration both directly by release of uPAR and by enhanced cleavage. These processes are not seen when the samples are kept at 4°C, which is in accordance with the fact that in general all biological processes proceed slowly at low temperatures.
In conclusion, this study indicates that future studies of suPAR in EDTA plasma and/or serum can be performed on whole blood that has been kept in the tube at 4°C up to three days before processing into serum and EDTA plasma, while whole blood can be kept at 20°C for 24 hours before centrifugation. In addition, our data show that repeated freezing/thawing cycles had no influence on sample suPAR values. In order to minimize the potential influence of any time dependency on suPAR levels all samples of whole blood should be kept for approximately the same time before processing into serum or EDTA plasma, but rapid processing and freezing of the samples is always preferable. 
